Vascular Smooth Muscle Cell Senescence And The Effects Of Oestrogen
Funder
National Health and Medical Research Council
Funding Amount
$191,370.00
Summary
The incidence of cardiovascular diseases is much lower in women before menopause, and this is thought to be due to a beneficial effect of oestrogen on the cardiovascular system. However the mechanisms of the hormone’s cardiovascular-protective actions are still not clear. The proposed project will determine whether oestrogen acts by slowing the natural ageing process of cells.
Exploring The Therapeutic Potential Of TRAIL In Diabetes And The Metabolic Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$446,374.00
Summary
TNF-related apoptosis-inducing ligand (TRAIL) is a protein with potentially useful actions in human health and disease. TRAIL is able to prevent atherosclerosis, the cause of heart attacks and strokes. In addition, we have recently shown that its actions on fat and the pancreas may prevent the development of the metabolic syndrome and type 2 diabetes. These studies will explore the therapeutic potential of TRAIL for the prevention of diabetes and heart disease in a range of animal models.
Novel Small Molecule FosB/AP-1 Inhibitors For The Prevention Of Proliferative Vascular Disorders
Funder
National Health and Medical Research Council
Funding Amount
$343,597.00
Summary
This project examines the effect of a novel FosB/AP-1 inhibitor (LK001) on neointima formation after injury in animal models of restenosis, atherosclerosis and abdominal aortic aneurysm, and a human ex vivo model of graft stenosis Given the current prevalence of CVD in Australia and the increasing demographic of susceptible individuals in the ageing population, this project has enormous clinical implications.
Mechanisms And Therapies In Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$8,360,700.00
Summary
Cardiovascular disease (CVD) claims 1 person every 10 min in Australia and causes 1 in 3 deaths worldwide. The molecular and cellular processes underlying atherosclerosis, vascular injury and thrombosis are highly complex and not well understood. A multifaceted approach is needed to effectively address these key challenges. This Program brings together world experts in these areas to interrogate gaps in our basic understanding of CVD, and to develop novel therapies for CVD patients by exploiting ....Cardiovascular disease (CVD) claims 1 person every 10 min in Australia and causes 1 in 3 deaths worldwide. The molecular and cellular processes underlying atherosclerosis, vascular injury and thrombosis are highly complex and not well understood. A multifaceted approach is needed to effectively address these key challenges. This Program brings together world experts in these areas to interrogate gaps in our basic understanding of CVD, and to develop novel therapies for CVD patients by exploiting new knowledge through integrated research.Read moreRead less
Activation Transcription Factor-4: Novel Regulator Of Smooth Muscle Cell Repair And Intimal Thickening Through Tenascin C
Funder
National Health and Medical Research Council
Funding Amount
$228,313.00
Summary
CVD represents the most important cause of morbidity and mortality in the world, accounting for 35% of all deaths in Australia. Smooth muscle cell growth accounts for a range of vascular proliferative disorders. This project focuses on understanding the role of ATF-4 as a new key regulator of SMC proliferation and intimal thickening in injured vessels. Moreover, strategies targeting ATF-4 will facilitate future therapeutic strategies to control intimal thickening in patients with vascular diseas ....CVD represents the most important cause of morbidity and mortality in the world, accounting for 35% of all deaths in Australia. Smooth muscle cell growth accounts for a range of vascular proliferative disorders. This project focuses on understanding the role of ATF-4 as a new key regulator of SMC proliferation and intimal thickening in injured vessels. Moreover, strategies targeting ATF-4 will facilitate future therapeutic strategies to control intimal thickening in patients with vascular disease.Read moreRead less